Key Takeaways
- Stand-alone margins improved sharply, but input costs are now rising: Stand-alone EBITDA margin expanded ~408 bps YoY in Q4, driven by mix and steady raw material costs, but management flagged a ~10%–12% material cost increase ahead as solvent and packaging prices spike.
- Unichem is the consolidated margin drag: Unichem's EBITDA margin fell from 12% to ~8% as U.S. turnover stalled, Ireland closure costs hit, and technology transfer expenses spiked; its recovery to 12%–13% is a key FY27 assumption.
- Domestic formulation remains the engine: Domestic branded business grew ~12% in Q4 and ~10% for FY26, beating the market, with a policy of ~5%–6% annual price increases and ~18–20 product launches per year.
- FY27 growth guided at ~12%–13% across most segments: Management expects India, CIS, promotional markets, and overall generics (including U.S.) all to grow in that range, with consolidated revenue growth also pegged at ~12%–13%.
- What to watch next quarter: Whether the ~10%–12% input cost increase materializes and how much of it can be passed through in domestic controlled portfolios, and whether Unichem's U.S. business shows the guided ~10% growth.
Stand-alone Margin Drivers & Input Cost Pressure
- Mix shift powered FY26 margin gains: Stand-alone EBITDA margin improved ~252 bps for FY26 as material cost declined ~2% despite ~10% revenue growth; the improvement came from a richer product mix — domestic business strong, ROW markets strong, cardiac proportion up, generic business delivering better margins, and API margins also improving.
- Raw material stability is ending: Prices were steady for the first 11 months of FY26, but in February–March, solvents, ammonia, and acid/alkali moved up; packaging materials (aluminum, PVC, PVDC) saw significant price increases, and solvents are now 40%–50% higher than January levels.
- Overall material cost expected to rise ~10%–12%: Management cited supply chain disturbances and elevated petroleum prices as drivers; however, the material cost ratio is only ~25% of sales, so the expected impact on the ratio is ~0.5%–0.75%, and top-line growth should absorb much of the absolute increase.
- API cost pass-through is clean, domestic formulations are not: The entire API cost increase is being passed on to buyers, but in the domestic market, price-controlled products cannot be increased by even a paisa; decontrolled products will see ~6%–7% price increases to offset input cost rises.
- Freight costs spiked late in the quarter: Freight costs rose ~25% in Q4, air freight multiplied, and cargo space availability became an issue due to Iran-U.S. conflict and Strait of Hormuz disruptions; management did not commit to a normalization timeline, arguing growth will offset the cost.
A.K. Jain: "As far as the domestic market is concerned, products which are in price control, the prices remain at the same level. You can't increase even a paisa on that."
Unichem: The Consolidation Overhang
- Margins collapsed on flat revenue: Unichem's EBITDA margin fell from 12% to ~8% in FY26 because turnover did not grow; the U.S. business lost market share on high-volume products, and the Ireland facility closure incurred severance and other costs that were fully debited in FY26.
- Q4 other expenses spiked on tech transfer costs: ~₹10 cr–₹12 cr in technology transfer costs were incurred for 4–5 products moving to third-party manufacturers for U.S. government institutional business; production shifted back to India, and air shipment was reduced from ~40% to ~4%–5% of volume.
- FY27 margin recovery guided to 12%–13%: Management expects Unichem's EBITDA margin to recover to that level in the current financial year, with further improvement in future years as filings in other markets come up and products launch; U.S. revenue is guided to grow ~10% in FY27.
- The recovery path is back-end loaded: Unichem should launch at least 5–6 products in the current year, but the margin improvement beyond 12%–13% depends on future filings and launches in other markets, which have no specific timeline.
A.K. Jain: "We foresee that I think Unichem margin may become around 12% to 13% in the current financial year from that level. And from that level, again in future years as our filings in other markets start coming up and then we start launching products in other markets. Margins will keep on improving."
Domestic Formulation: The Steady Compounders
- Chronic and acute both beating the market: Domestic formulation grew ~12% in Q4 and ~10% for FY26, with both segments outperforming; FY27 growth is guided at ~12%, with 1%–2% from new products and the balance from price increases and volume.
- Price increase policy is systematic: Management targets ~5%–6% annual price increases in the domestic market, depending on competitor actions; decontrolled products will see ~6%–7% increases in FY27 to offset input cost pressure.
- Launch philosophy favors focus over volume: The company launches ~18–20 products per year across ~20 divisions, with each division launching roughly one product or line extension; management deliberately avoids launching too many products to prevent defocus from power brands.
A.K. Jain: "More number of products you launch, the attention of the people get diluted and that results in the overall defocus from the main power brands."
Export Formulation & API
- Branded exports led FY26 growth: Promotional branded exports grew ~14% and generic ex-tenders grew ~17%, while institutional business declined; overall export formulation grew ~9% for FY26.
- FY27 export growth guided at 12%–13% in INR terms: CIS market expected to grow ~10%–11%, overall promotional markets ~12%–13%, and overall generics (including U.S.) ~12%–13%; U.S. generics should see ~6–8 products commercialized in the current financial year.
- API business grew ~10% in FY26: Margins improved alongside the top line, and management stated the entire cost increase in API is being passed on to buyers with no issues.
- Other markets follow a steady cadence: European and other generic markets normally see 3–4 product launches per market per year.
Subsidiaries & Associates: Mixed Bag
- Trophic Wellness was the standout: The nutraceuticals subsidiary delivered ~₹125 cr in revenue and ~₹40 cr+ in profit.
- Krebs is turning the corner: The Nellore plant turned EBITDA positive; the other plant has polishing department issues that, once resolved, should also become EBITDA positive.
- Onyx Scientific and U.K. subsidiary remain weak: Onyx is seeing lower inquiry levels for research services but management noted signs of improvement after 1–1.5 years of issues; the U.K. formulation subsidiary had a small loss due to bad pricing, though shortages and price improvement offer some hope.
- Pisgah Labs formulation facility is a FY28 story: The U.S. API facility has a good order position, and a formulation facility is under construction with commissioning expected in Q4 FY27; meaningful turnover will only come in FY28.
- Lyka Labs performance is deteriorating: The associate is spending significantly on field force for injectables and animal health care, depressing current profitability; management declined to comment on impairment risk, deferring to Lyka Labs directly.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Consolidated revenue growth | ~12%–13% | FY27 |
| Consolidated EBITDA margin | Improve from 20.7% to ~22% or 22.3% | FY27 |
| Stand-alone EBITDA margin | Improve by ~1%–1.25% (lowered from ~1.5%+ due to material cost) | FY27 |
| Unichem EBITDA margin | Recover to 12%–13% | FY27 |
| Unichem U.S. revenue growth | ~10% | FY27 |
| Unichem product launches | At least 5–6 products | FY27 |
| Domestic formulation growth | ~12% (1%–2% from new products, balance price and volume) | FY27 |
| U.S. generics commercialization | 6–8 products | FY27 |
| Overall material cost increase | ~10%–12%, with ~0.5%–0.75% impact on material cost ratio | FY27 (conditional on petroleum prices holding) |
| Decontrolled product price increase | ~6%–7% | FY27 |
| Pisgah Labs formulation facility | Commissioning | Q4 FY27 |
| Pisgah Labs meaningful turnover | Revenue contribution begins | FY28 |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Consolidated revenue | ₹2,388 cr, +6% YoY |
| Consolidated revenue (FY26) | ₹9,646 cr, +8% YoY |
| Stand-alone EBITDA margin | 25.27%, vs 21.19% in Q4 FY25, improvement of ~4.08 ppt |
| Stand-alone EBITDA margin (FY26) | 25.18%, vs 22.66% in FY25, improvement of ~2.52 ppt |
| Consolidated EBITDA margin | 20.52%, vs 18.24% in Q4 FY25, improvement of ~2.28 ppt |
| Consolidated EBITDA margin (FY26) | 20.72%, vs 19.94% in FY25, improvement of ~1.78 ppt |
| Domestic formulation revenue | ₹853 cr, +12% YoY |
| Domestic formulation revenue (FY26) | ₹3,817 cr, +10% YoY |
| Export formulation revenue (FY26) | ₹2,083 cr, +9% YoY |
| Promotional branded export revenue (FY26) | ₹664 cr, +14% YoY |
| Generic business revenue, ex-tenders (FY26) | ₹1,149 cr, +17% YoY |
| Institutional business revenue | ₹74 cr, -33% YoY |
| API business revenue (FY26) | ₹1,396 cr, +10% YoY |
| Consolidated U.S. business revenue | ₹428 cr, +10% YoY |
| Consolidated U.S. business revenue (FY26) | ₹1,567 cr, +14% YoY |
| Unichem EBITDA margin (FY26) | ~8%, declined from 12% in FY25 |
| Domestic market share (MAT March '26) | 2.09%, vs 2.08% in MAT December '25 |
| Freight cost increase | ~25% QoQ |
| Material cost to sales ratio (stand-alone) | 25% |
| Unichem R&D spend (FY26) | 3.71% of sales |
| Unichem Ireland overhead cost savings (FY27) | EUR 4 mn–EUR 5 mn per year, expenditure stopping |
| FY27 consolidated revenue growth guidance | 12%–13% |
| FY27 consolidated EBITDA margin guidance | ~22%–22.3% |
| FY27 Unichem EBITDA margin guidance | 12%–13% |
| FY27 domestic branded growth guidance | ~12%, with 1%–2% from new products |